The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Leng, Weiling ^a   Ouyang, Xinshou ^b   Lei, Xiaotian ^a   Wu, Mingxia ^a   Chen, Liu ^a   Wu, Qinan ^a   Deng, Wuquan ^a   Liang, Ziwen ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CRYOPYRIN; DAPAGLIFLOZIN; EOSIN; GLUCOSE; HEMATOXYLIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; INFLAMMASOME; NLRP3 PROTEIN, MOUSE; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EXPERIMENTAL ATHEROSCLEROSIS; GLUCOSE METABOLISM; KNOCKOUT MOUSE; LIPID DIET; LIPID METABOLISM; MACROPHAGE; MALE; MOUSE; NONHUMAN; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THERAPY EFFECT; TREATMENT DURATION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; ATHEROSCLEROSIS; BONE MARROW; C57BL MOUSE; COMPLICATION; DIABETES COMPLICATIONS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BONE MARROW; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLUCOSIDES; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; REACTIVE OXYGEN SPECIES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85009349867     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/6305735     Document Type: Article

References (34)

1. P. Libby, P. M. Ridker, A. Maseri, "Inflammation, atherosclerosis, " Circulation, vol. 105, no. 9, pp. 1135-1143, 2002.
2. G. K. Hansson, "Inflammation, atherosclerosis, coronary artery disease, " The New England Journal of Medicine, vol. 352, no. 16, pp. 1685-1695, 2005.
3. G. K. Hansson, P. Libby, "The immune response in atherosclerosis: a double-edged sword, " Nature Reviews Immunology, vol. 6, no. 7, pp. 508-519, 2006.
4. R. Kleemann, S. Zadelaar, T. Kooistra, "Cytokines, atherosclerosis: a comprehensive review of studies in mice, " Cardiovascular Research, vol. 79, no. 3, pp. 360-376, 2008.
5. O. Takeuchi, S. Akira, "Pattern recognition receptors, inflammation, " Cell, vol. 140, no. 6, pp. 805-820, 2010.
6. S. L. Cassel, S. Joly, F. S. Sutterwala, "The NLRP3 inflammasome: a sensor of immune danger signals, " Seminars in Immunology, vol. 21, no. 4, pp. 194-198, 2009.
7. W. P. Arend, G. Palmer, C. Gabay, "IL-1, IL-18, IL-33 families of cytokines, " Immunological Reviews, vol. 223, no. 1, pp. 20-38, 2008.
8. P. Duewell, H. Kono, K. J. Rayner et al. , "NLRP3 inflammasomes are required for atherogenesis, activated by cholesterol crystals, " Nature, vol. 464, no. 7293, pp. 1357-1361, 2010.
9. F. Zheng, S. Xing, Z. Gong, W. Mu, Q. Xing, "Silence of NLRP3 suppresses atherosclerosis, stabilizes plaques in apolipoprotein E-deficient mice, " Mediators of Inflammation, vol. 2014, Article ID 507208, 8 pages, 2014.
10. H. Kirii, T. Niwa, Y. Yamada et al. , "Lack of interleukin-1 decreases the severity of atherosclerosis in ApoE-deficient mice, "Arteriosclerosis, Thrombosis, Vascular Biology, vol. 23, no. 4, pp. 656-660, 2003.
11. F. Merhi-Soussi, B. R. Kwak, D. Magne et al. , "Interleukin-1 plays a major role in vascular inflammation, atherosclerosis in male apolipoprotein E-knockout mice, " Cardiovascular Research, vol. 66, no. 3, pp. 583-593, 2005.
12. Z. Mallat, A. Corbaz, A. Scoazec et al. , "Expression of interleukin-18 in human atherosclerotic plaques, relation to plaque instability, " Circulation, vol. 104, no. 14, pp. 1598-1603, 2001.
13. E. Ferrannini, S. J. Ramos, A. Salsali, W. Tang, J. F. List, "Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet, exercise: a randomized, double-blind, placebo-controlled, phase 3 trial, " Diabetes Care, vol. 33, no. 10, pp. 2217-2224, 2010.
14. L. Ji, J. Ma, H. Li et al. , "Dapagliflozin as monotherapy in drugnaive asian patients with type 2 diabetesmellitus: a randomized, blinded, prospective phase III study, " Clinical Therapeutics, vol. 36, no. 1, pp. 84. e9-100. e9, 2014.
15. D. E. Kohan, P. Fioretto, W. Tang, J. F. List, "Long-termstudy of patients with type 2 diabetes, moderate renal impairment shows that dapagliflozin reduces weight, blood pressure but does not improve glycemic control, " Kidney International, vol. 85, no. 4, pp. 962-971, 2014.
16. J. Bolinder, O. Ljunggren, J. Kullberg et al. , "Effects of dapagliflozin on body weight, total fat mass, regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin, " Journal of Clinical Endocrinology, Metabolism, vol. 97, no. 3, pp. 1020-1031, 2012.
17. T. Nagata, T. Fukuzawa, M. Takeda et al. , "Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal, pancreatic function in db/db mice, " British Journal of Pharmacology, vol. 170, no. 3, pp. 519-531, 2013.
18. N. Terami, D. Ogawa, H. Tachibana et al. , "Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis, diabetic nephropathy in db/db mice, " PLoS ONE, vol. 9, no. 6, Article ID e100777, 2014.
19. A. Merovci, C. Solis-Herrera, G. Daniele et al. , "Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production, " The Journal of Clinical Investigation, vol. 124, no. 2, pp. 509-514, 2014.
20. A. Tahara, E. Kurosaki, M. Yokono et al. , "Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, obesity in type 2 diabetic mice, " European Journal of Pharmacology, vol. 715, no. 1-3, pp. 246-255, 2013.
21. D. Z. I. Cherney, B. A. Perkins, N. Soleymanlou et al. , "Theeffect of empagliflozin on arterial stiffness, heart rate variability in subjects with uncomplicated type 1 diabetes mellitus, " Cardiovascular Diabetology, vol. 13, no. 1, article 28, 2014.
22. S. Zadelaar, R. Kleemann, L. Verschuren et al. , "Mouse models for atherosclerosis, pharmaceutical modifiers, " Arteriosclerosis, Thrombosis, Vascular Biology, vol. 27, no. 8, pp. 1706-1721, 2007.
23. M. Chai, Q. Ji, H. Zhang et al. , "The protective effect of interleukin-37 on vascular calcification, atherosclerosis in apolipoprotein E-deficient mice with diabetes, " Journal of Interferon, Cytokine Research, vol. 35, no. 7, pp. 530-539, 2015.
24. R. E. Pratley, "The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes, " Current Diabetes Reports, vol. 6, no. 1, pp. 45-46, 2006.
25. J. Armitage, L. Bowman, "Cardiovascular outcomes among participants with diabetes in the recent large statin trials, " Current Opinion in Lipidology, vol. 15, no. 4, pp. 439-446, 2004.
26. A. S. Wierzbicki, J. Morrell, D. Hemsley, Z. McMahon, M. A. Crook, R. Wray, "The effect of fibratestatin combination therapy on cardiovascular events: a retrospective cohort analysis, " Current Medical Research, Opinion, vol. 26, no. 9, pp. 2141-2146, 2010.
27. M. Terasaki, M. Hiromura, Y. Mori et al. , "Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1, type 2 diabetic mice, " PLOS ONE, vol. 10, no. 11, Article ID e0143396, 2015.
28. S. Legrand-Poels, N. Esser, L. L'Homme, A. Scheen, N. Paquot, J. Piette, "Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes, " Biochemical Pharmacology, vol. 92, no. 1, pp. 131-141, 2014.
29. H. J. Williams, E. A. Fisher, D. R. Greaves, "Macrophage differentiation, function in atherosclerosis: opportunities for therapeutic intervention" Journal of Innate Immunity, vol. 4, no. 5-6, pp. 498-508, 2012.
30. P. Lacolley, V. Regnault, A. Nicoletti, Z. Li, J.-B. Michel, "The vascular smoothmuscle cell in arterial pathology: a cell that can take on multiple roles, " Cardiovascular Research, vol. 95, no. 2, pp. 194-204, 2012.
31. R. Zhou, A. Tardivel, B. Thorens, I. Choi, J. Tschopp, "Thioredoxin-interacting protein links oxidative stress to inflammasome activation, " Nature Immunology, vol. 11, no. 2, pp. 136-140, 2010.
32. H. Wen, D. Gris, Y. Lei et al. , "Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, " Nature Immunology, vol. 12, no. 5, pp. 408-415, 2011.
33. M. Lee, "Role of innate immunity in diabetes, metabolism: recent progress in the study of inflammasomes, " Immune Network, vol. 11, no. 2, pp. 95-99, 2011.
34. E. Di Marco, S. P. Gray, P. Chew et al. , "Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS, immune-inflammatory responses in diabetic Apoe/mice, " Diabetologia, vol. 57, no. 3, pp. 633-642, 2014.